Safety biomarkers and the clinical development of oncology therapeutics: Considerations for cardiovascular safety and risk management

AAPS Journal

Volumn 8, Issue 1, 2006, Pages

  Fingert, Howard ^a   Varterasian, Mary ^a  

^a PFIZER INC   (United States)

Author keywords

Cardiotoxicity; Oncology therapeutics; Risk management; Safety biomarkers

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PALIFERMIN; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; TROPONIN I;

ADVANCED CANCER; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL LABORATORY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST OF ILLNESS; DECISION MAKING; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; ECHOCARDIOGRAPHY; EDEMA; ELECTROLYTE DISTURBANCE; EXPERIMENTAL DESIGN; FATIGUE; FEBRILE NEUTROPENIA; HEALTH CARE ACCESS; HEALTH PROGRAM; HEART ARRHYTHMIA; HEART DISEASE; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; LABORATORY DIAGNOSIS; LEUKEMIA; MAXIMUM TOLERATED DOSE; NEUTROPENIA; ONCOLOGY; PATIENT CARE; PREDICTION; QT INTERVAL; QT PROLONGATION; RADIOLOGICAL PROCEDURES; REGISTRATION; RISK MANAGEMENT; SOLID TUMOR; STOMATITIS; TORSADE DES POINTES; TREATMENT WITHDRAWAL;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS; DECISION MAKING; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASMS; RISK MANAGEMENT; TECHNOLOGY, PHARMACEUTICAL; VENTRICULAR FUNCTION, LEFT;

EID: 33645087114     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj080110     Document Type: Article

References (18)

1. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490-1496.
2. CTC v2.0 and CTCAE v3.0 Webpage. National Cancer Institute. Available at: http://ctep.cancer.gov/reporting/ctc.html. Accessed March 1, 2006.
3. Official Website. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Available at: http://www.ich.org. Accessed March 1, 2006.
4. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005;23: 7685-7696.
5. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122-3131.
6. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable Her-2 positive breast cancer. N Engl J Med. 2005;353:1673-1684.
7. Perez E.A, Suman VJ, Davidson NE. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. In: J Clin Oncol. vol. 23(suppl):17s. 2005:Abstract 556.
8. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol. 2005;16:1391-1397.
9. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23:2900-2902.
10. Burris HA III, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a dual reversible inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005;23:5305-5313.
11. Isotalo PA, Greenway DC, Donnelly JG. Metastatic alveolar rhabdomyosarcoma with increased serum creatine kinase MB and cardiac troponin T and normal cardiac troponin I. Clin Chem. 1999;45:1576-1578.
12. Britten CD, Rowinsky EK, Soignet C, et al. A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin Cancer Res. 2001;7:3894-3903.
13. Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003;21:3609-3615.
14. Varterasian M, Meyer M, Fingert H, et al. Baseline heart rate-corrected QT and eligibility for clinical trials in oncology. J Clin Oncol. 2003;21:3378-3379.
15. Piotrovsky V. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J. 2005;7:E609-E624.
16. Varterasian M, Fingert H, Agin M, et al. Consideration of QT/QTc interval data in a phase I study in patients with advanced cancer. Clin Cancer Res. 2004; 10:5967-5970.
17. Morganroth J, Brozovich FV, McDonald JT, et al. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol. 1991;67:774-776.
18. Furberg B. Surrogate markers - substitute measurements: easy to measure but irrelevant? Lakartidningen. 2002;99:1672-1675 In Swedish.